Cargando…

Difference of molecular alterations in HER2-positive and HER2-negative gastric cancers by whole-genome sequencing analysis

OBJECTIVE: The aim of this study was to compare the molecular profiling, including somatic mutation and somatic copy number variation (SCNV), between human epidermal growth factor receptor 2 (HER2)-positive (HER2+) and HER2-negative (HER2−) gastric cancer patients. PATIENTS AND METHODS: Tumor sample...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Chenfei, Feng, Xiaojing, Yuan, Fei, Ji, Jun, Shi, Min, Yu, Yingyan, Zhu, Zhenggang, Zhang, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165778/ https://www.ncbi.nlm.nih.gov/pubmed/30310315 http://dx.doi.org/10.2147/CMAR.S172710

Ejemplares similares

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
por: Morsberger, Laura, et al.
Publicado: (2022)

HER2-positive gastric cancer
por: Boku, Narikazu
Publicado: (2013)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
por: Ishimine, Yu, et al.
Publicado: (2015)

HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
por: Kaito, Akio, et al.
Publicado: (2019)

Antitumor activity of pan‐HER inhibitors in HER2‐positive gastric cancer
por: Yoshioka, Takahiro, et al.
Publicado: (2018)

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
por: Liu, Binliang, et al.
Publicado: (2022)

Neratinib for HER2-positive breast cancer with an overlooked option
por: Guo, Liting, et al.
Publicado: (2023)

HER2-positive gastric cancer identified by serum HER2: A case report
por: SAITO, MAYUKO, et al.
Publicado: (2016)

Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer
por: Yoshikawa, Ayumu, et al.
Publicado: (2022)

From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer
por: Sun, Jiangang, et al.
Publicado: (2022)

Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
por: Laidi, Fatna, et al.
Publicado: (2014)

MTA2 enhances colony formation and tumor growth of gastric cancer cells through IL-11
por: Zhou, Chenfei, et al.
Publicado: (2015)

Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer
por: Kim, Yun Gyoung, et al.
Publicado: (2017)

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
por: Grüntkemeier, Lisa, et al.
Publicado: (2022)

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers
por: Ferrari, Anthony, et al.
Publicado: (2016)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
por: Shikata, Shohei, et al.
Publicado: (2023)

MTA2 promotes gastric cancer cells invasion and is transcriptionally regulated by Sp1
por: Zhou, Chenfei, et al.
Publicado: (2013)

Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro
por: Leis-Filho, Antonio Fernando, et al.
Publicado: (2021)

HER2 Positive and HER2 Negative Classical Type Invasive Lobular Carcinomas: Comparison of Clinicopathologic Features
por: He, Lin, et al.
Publicado: (2021)

Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer
por: Kang, Byeongju, et al.
Publicado: (2023)

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
por: Wakatsuki, Takeru, et al.
Publicado: (2018)

HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma
por: Liu, Zimin, et al.
Publicado: (2021)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018)

Nomograms Involving HER2 for Predicting Lymph Node Metastasis in Early Gastric Cancer
por: Mei, Yu, et al.
Publicado: (2021)

Are There More HER2 FISH in the Sea? An Institution’s Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry
por: Suydam, Camille, et al.
Publicado: (2023)

The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer
por: Lee, Ji Yun, et al.
Publicado: (2015)

Expression pattern of CDK12 protein in gastric cancer and its positive correlation with CD8(+) cell density and CCL12 expression
por: Ji, Jun, et al.
Publicado: (2019)

PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
por: Kim, Chan, et al.
Publicado: (2017)

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
por: Kurozumi, Sasagu, et al.
Publicado: (2016)

HER2 Positive Gastric Carcinomas and Their Clinico-Pathological Characteristics
por: Ognjenovic, Ljubomir, et al.
Publicado: (2018)

Challenges and future of HER2-positive gastric cancer therapy
por: Ma, Chenzhe, et al.
Publicado: (2023)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer
por: Maddox, Adam L., et al.
Publicado: (2022)

HER2/positive and HER2/low in inflammatory breast cancer recurrence
por: Movchan, Oleksii Volodimirovich, et al.
Publicado: (2022)

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
por: Loibl, Sibylle, et al.
Publicado: (2022)

Targeting HER2-positive gastric cancer with a novel (18)F-labeled Z(HER2:342) probe
por: Pan, Yunyun, et al.
Publicado: (2019)

Genomic characterization between HER2‐positive and negative gastric cancer patients in a prospective trial
por: Hu, Qingjiang, et al.
Publicado: (2023)

Oncogenic HER2 fusions in gastric cancer
por: Yu, De-Hua, et al.
Publicado: (2015)

CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer
por: Sun, Weilin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qkc4ga4benqhtdmncdnn8tksbn